Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Belgium / NCT07621783
Recruiting Observational

Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context

NCT07621783 · tracked via the Priya Life Science Belgium tracker
Sponsor
Imelda GI Clinical Research Center
Phase
Observational
Started
2026-05-01
Last updated
2026-06-02

Condition(s) studied

Crohn Disease (CD)Ulcerative Colitis (UC)

Investigational drug(s) / intervention(s)

Leucine-rich α2-glycoprotein

Leucine-rich α2-glycoprotein: Leucine-rich α2-glycoprotein measurement

Study summary

Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical/endoscopic/histological disease activity in patients with inflammatory bowel disease (IBD) in Europe.

Eligibility

Sex
ALL
Min age
16 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. ≥18 years 2. Patient with confirmed diagnosis of IBD 3. Patient with planned endoscopy (ileocolonoscopy for Crohn's disease (CD)/ulcerative colitis (UC) or sigmoidoscopy for UC) for the assessment of endoscopic disease activity according to routine practice 4. willing to provide informed consent Exclusion Criteria: 1. Patient with IBD unspecified 2. Patient with ileo- or colostomy 3. Patient with total colectomy 4. Women that are pregnant

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Imelda General Hospital Bonheiden Belgium Recruiting

More Imelda GI Clinical Research Center trials in Belgium

Multiple Digital Biomarkers for Optimization of IBD Care Starting soon

Other trials for the same condition

A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease Recruiting
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis Active, not recruiting
Multiple Digital Biomarkers for Optimization of IBD Care Starting soon
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) Active, not recruiting
AI-driven Narrow-band Imaging Score for Disease Assessment and Outcome Prediction in Ulcerative Colitis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07621783 on ClinicalTrials.gov ↗ ← All trials in Belgium